Guggenheim raises Tempus AI stock price target to $95 on oncology AI model
PositiveFinancial Markets

Guggenheim has raised its stock price target for Tempus AI to $95, highlighting the company's promising oncology AI model. This adjustment reflects growing confidence in Tempus AI's innovative approach to cancer treatment, which could significantly impact patient care and the healthcare industry as a whole. Investors are likely to view this as a positive sign for the company's future prospects.
— Curated by the World Pulse Now AI Editorial System